FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient ...

Biomarkers such as ring sideroblasts are indicators for response to treatments like luspatercept (Reblozyl). In patients with ...

Comprehensive biomarker testing is central to the management of metastatic non-small cell lung cancer (NSCLC). Widespread ...

While this panel has grown in recent years, many experts believe additional biomarkers should also be incorporated as ...

Lifileucel showed a 31.4% objective response rate and a median duration of response of 36.5 months in advanced melanoma patients. The median overall survival was 13.9 months, with adverse events ...

The FDA has approved durvalumab (Imfinzi) plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for the treatment ...

AVZO-103 has received fast track designation for treating urothelial cancer patients previously treated with enfortumab ...

Sonrotoclax (BGB-11417), an investigational, next-generation BCL2 inhibitor, has received priority review designation from the FDA for the treatment of adult patients with relapsed or refractory (R/R) ...

The subcutaneous formulation of toripalimab demonstrated noninferior pharmacokinetics compared to the intravenous version in treating nonsquamous NSCLC. The study confirmed comparable efficacy and ...

A phase 2 study reveals high efficacy and manageable safety of venetoclax plus obinutuzumab for untreated CLL/SLL in Japanese ...

The PACIFIC-2 trial reveals that durvalumab with chemoradiotherapy offers no survival benefits for stage 3 NSCLC and ...

Benjamin George, MD, has significantly improved cancer care access in rural Nebraska, Colorado, and Kansas, transforming ...